Nexalin Technology (NXL) Long-Term Deferred Tax (2021 - 2022)
Nexalin Technology's (NXL) quarterly Long-Term Deferred Tax came in at $3.3 million in Q4 2022, up 12.91% year-on-year from $3.0 million in Q4 2021, and up 12.91% quarter-over-quarter from $3.0 million in Q4 2021.
Nexalin Technology (NXL) Long-Term Deferred Tax (2021 - 2022) Analysis & Trends
Nexalin Technology's Long-Term Deferred Tax history runs 2 years deep, the most recent figure standing at $3.3 million for Q4 2022.
- On a quarterly basis, Long-Term Deferred Tax rose 12.91% year-over-year to $3.3 million in Q4 2022; TTM through Dec 2022 was $3.3 million, a 12.91% increase from a year earlier, with the FY2022 full-year figure at $3.3 million, up 12.91% from the prior year.
- Long-Term Deferred Tax advanced to $3.3 million in Q4 2022 per NXL's latest filing, from $3.0 million in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $3.3 million in Q4 2022 and bottomed at $3.0 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | Nexalin Technology | 9.32 Mn | 6.61 Mn | 13,133.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 3.34 Mn |
| Dec 31, 2021 | 2.96 Mn |